EGFR and neoplasm: 1. Loss of expression of tumor-associated antigens[43]2. Impairment of antigen processing and delivery[44]3. Persistent upregulation of PD-L1 expression on the surface of tumor cells[45]4. Apoptotic resistance in tumor cells[46,47]5. Induced dormancy and senescence of tumor cells[48]6. Tumor cells undergo dedifferentiation and EMT[49]7. MDM2/MDM4 amplification and EGFR mutation[58]